Finally, in support of the notion that BAF treatment augments the BBR-induced cell death, we demonstrated that co-treatment of the hepatoma cells with low concentration of both agents (5 nM BAF and 5 μM BBR) for 48 h significantly induced the hepatoma cell death to a similar degree to BBR alone at 100 μM (Figure S1), which suggested the anti-HCC potency of the combination treatment. This evidence concerns the gene BANF1 and hepatocellular carcinoma.